LDL and Beyond: Current and Future Approaches to Cholesterol Management

Great Neck, NY

Vertical Tabs

Overview

Activity Overview

Statins have been the cornerstone of lipid therapy for decades and low-density lipoprotein C has been the primary target of intervention.  However, the management of dyslipidemia is much more complex than this.  The difficulty of reaching increasingly more stringent LDL-C goals and emerging data, including major outcome trials, and the potential for new treatment targets and agents with which to address them, may usher in a new era of lipid management. Updated treatment guidelines have been eagerly awaited that incorporate new learning’s. This continuing education program will bring together expert faculty to review where we are and where we are going with dyslipidemia management…LDL and Beyond: Current and Future Approaches to Cholesterol Management.

Target Audience

This activity is intended for  Endocrinologists, Fellows in Clinical Practice and Clinical Researchers.

  

LEARNER BILL OF RIGHTS

The American Association of Clinical Endocrinologists (AACE) recognizes that you are a life-long learner who has chosen to engage in continuing medical education to identify or fill a gap in knowledge, skill or performance.  As part of AACE’s duty to you as a learner, you have the right to expect that your continuing medical education experience with AACE includes:

 

CONTENT that:

  • Promotes improvements or quality in healthcare;
  • Is valid, reliable and accurate;
  • Offers balanced presentations that are free of commercial bias for or against a product/service;
  • Is vetted through a process that resolves any conflicts of interests of planners, teachers or authors;
  • Is driven and based on learning needs, not commercial interests;
  • Addresses the stated objectives or purpose; and
  • Is evaluated for its effectiveness in meeting the identified educational need.

 

A LEARNING ENVIRONMENT that:

  • Supports learners’ ability to meet their individual needs;
  • Respects and attends to any special needs of the learners;
  • Respects the diversity of groups of learners; and
  • Is free of promotional, commercial and/or sales activities.

 

DISCLOSURE of:

  • Relevant financial relationships planners, teachers and authors have with commercial interests related to the content of the activity; and
  • Commercial support (funding or in-kind resources) of the activity.

 

 

Agenda

LDL and Beyond: Current and Future Approaches to Cholesterol Management

Wednesday, November 13, 2013

 

 

  6:30 pm

  Registration

  7:00 pm - 7:10 pm

  Welcome & Introduction

  7:10 pm - 7:30 pm

  CVD: 

  Epidemiology, Pathophysiology & Treatment Goals for Prevention

  7:30 pm - 7:50 pm

  Aggressive LDL Risk Reduction in the Modern Era:

  Monotherapy and Beyond

  7:50 pm - 8:10 pm

  Beyond LDL, The Residual Risk: Managing High TGL and Low HDL:

  Focus on Non HDL

  8:10 pm - 8:30 pm

  Future Options for the Management of Dyslipidemia:

  Clinical Data from Novel Classes of Drugs

  8:30 pm - 8:45 pm

  Panel Discussion:  

  What Will/Does ATP IV Do For Clinicians?

  8:45 pm

  Adjourn

Faculty

Paul S. Jellinger, MD, MACE - Chair

Professor of Clinical Medicine

University of Miami

School of Medicine

Miami, FL

The Center for Diabetes & Endocrine Care

Hollywood, FL

 

Paul D. Rosenblit, MD, PhD, FACE, FNLA

Clinical Professor, Medicine (Division of Endocrinology, Diabetes, Metabolism)

University California, Irvine (UCI), School of Medicine

Irvine, CA

Co-Director Diabetes Out-Patient Clinic, UCI Medical Center

Orange, CA

Director, Diabetes/Lipid Management & Research Center

Huntington Beach, CA

 

Educational Objectives

After participating in this activity, learners will be better able to:

  • Describe why many patients require therapy that targets more than one lipid parameter.
  • Explain how multiple lipid risk factors contribute to a patient's total risk profile.
  • Interpret data on the merits of targeting low LDL-C goals, triglycerides and HDL to improve patient’s CV risk profiles.
  • Evaluate emerging data on novel agents that modify lipids.
  • Consider how if the anticipated ATPIV will alter clinical practice recommendations for your patients with dyslipidemia or will the medical community turn to others for leadership in lipid management and prevention of CVD.
Steering/Program Committee

Chair

 Yehuda Handelsman, MD, FACP, FACE, FNLA

Medical Director, Metabolic Institute of America

Tarzana, CA

 

Members

 Alan J. Garber, MD, PhD, FACE

Professor, Departments of Medicine,

Biochemistry and Molecular Biology, and

Molecular and Cellular Biology

Baylor College of Medicine

Houston, TX

 

George Grunberger, MD, FACP, FACE

Chairman, Grunberger Diabetes Institute

Clinical Professor, Department of Internal Medicine Center

for Molecular Medicine & Genetics

Wayne State University School of Medicine

Bloomfield Hills, MI

 

Chris K. Guerin, MD, FACE, FNLA

Assistant Clinical Professor of Medicine University of California

San Diego, CA

 

Paul S. Jellinger, MD, MACE

Professor of Clinical Medicine

University of Miami

School of Medicine

Miami, FL

The Center for Diabetes & Endocrine Care

Hollywood, FL

 

Paul D. Rosenblit, MD, PhD, FACE, FNLA

Clinical Professor, Medicine (Division of Endocrinology, Diabetes, Metabolism)

University California, Irvine (UCI), School of Medicine

Irvine, CA

Co-Director Diabetes Out-Patient Clinic, UCI Medical Center

Orange, CA

Director, Diabetes/Lipid Management & Research Center

Huntington Beach, CA

 

Kathleen L. Wyne, MD, PhD, FACE

Director of Clinical Research

Diabetes Research Center

Weill Cornell Medical College

Houston, TX

Corporate Support

This is activity is supported by an educational donation provided by Amgen, Inc.

 

Physician Credit

This activity has been approved for AMA PRA Category 1 Credit(s)™. 

Location

Morton's The Steakhouse

777 Northern Boulevard

Great Neck, NY  11020

 

Register
Program Fee
There is no registration fee to attend this meeting. We do request that you pre-register by completing this form. AACE Membership is NOT required to attend this program.
Registration Type
Contact Information
Cancellation Policy
AACE reserves the right to cancel this course based on enrollment or conditions beyond our control. In the case of program cancellation, each pre-registrant will be notified by phone and/or email. AACE is not responsible for any costs incurred due to program cancellation, such as airline or hotel penalties.
E-mail Disclaimer
By entering your email address, you agree that your email address can be used for future correspondence from the American Association of Clinical Endocrinologists. This information would include, but is not limited to certifications, program information and future advertisements.
Finish Registration
A Printed Syllabus will NOT be distributed for this activity.
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.